- Home
- CHRO
as 07-26-2024 4:00pm EST
Stocks
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | NORTH BRUNSWICK |
| Market Cap: | 6.7M | IPO Year: | 2024 |
| Target Price: | N/A | AVG Volume (30 days): | 27.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.06 - $6.00 | Next Earning Date: | 08-20-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Chromocell Therapeutics Corporation (CHRO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Friedberg Ezra M | CHRO | Director | Feb 21 '24 | Buy | $6.00 | 16,667 | $100,002.00 | 545,721 | SEC Form 4 |
Latest Chromocell Therapeutics Corporation News
CHRO Breaking Stock News: Dive into CHRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Chromocell to Participate in the Virtual Investor Lunch Break Series
Newsfile
2 months ago
Edge Total Intelligence Inc. Updates Status of MCTO
CNW Group
2 months ago
HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
GlobeNewswire
2 months ago
LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting
GlobeNewswire
2 months ago
Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers
GlobeNewswire
2 months ago
The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024
GlobeNewswire
2 months ago
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
Compare CHRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CHRO Chromocell Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.